For the year ending 2025-12-31, GALT had $2,600K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -30,836 |
| Amortization of right to use asset | 53 |
| Stock-based compensation expense | 1,659 |
| Non-cash interest expense | 1,094 |
| Change in fair value of derivatives | 3,546 |
| Prepaid expenses and other assets | -416 |
| Accrued interest on convertible notes payable and convertible line of credit related party | 6,235 |
| Accounts payable, accrued expenses and other liabilities | -6,042 |
| Net cash from operating activities | -23,875 |
| Net cash from investing activities | 0 |
| Net proceeds from convertible line of credit related party | 21,000 |
| Net proceeds from issuance of common stock | 3,235 |
| Net proceeds from exercise of common stock options and warrants | 2,240 |
| Net cash from financing activities | 26,475 |
| Net increase (decrease) in cash and cash equivalents | 2,600 |
| Cash and cash equivalents, beginning of period | 15,120 |
| Cash and cash equivalents, end of period | 17,720 |
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)